HKPD Cellyan Biotechnology Co., Ltd IFRS Annual reports only
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 2007702 · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-03-31 | FY20242024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20.31M | $16.69M |
| Cost of revenue | $17.90M | $13.13M |
| Gross profit | $2.42M | $3.56M |
| SG&A expense | $2.22M | $1.89M |
| Operating income | -$2.28M | -$1.95M |
| Interest expense | $97,667 | $82,766 |
| Pretax income | $36,112 | $1.53M |
| Income tax | $63,168 | $196,252 |
| Net income | -$27,056 | $1.33M |
| EBITDA | -$2.22M | -$1.90M |
| EPS (basic) | -0.00 | 0.18 |
| EPS (diluted) | -0.00 | 0.18 |
| Weighted avg. shares (diluted) | 10.21M | 7.37M |
| Banking | ||
| Loans, net | $1.88M | $1.33M |
| Balance sheet | ||
| Cash & equivalents | $748,721 | $619,575 |
| Short-term investments | $284,546 | $261,877 |
| Receivables | $4.66M | $3.70M |
| Inventory | $559,982 | $933,299 |
| Current assets | $8.73M | $7.80M |
| PP&E, netmay include right-of-use assets (IFRS) | $111,245 | $103,242 |
| Total assets | $9.42M | $8.67M |
| Current liabilities | $2.92M | $3.18M |
| Short-term debt | $371,558 | $34,704 |
| Long-term debt | $1.50M | $1.12M |
| Total debt | $1.88M | $1.15M |
| Total liabilities | $4.43M | $4.41M |
| Shareholders' equity | $4.99M | $4.25M |
| Net debt | $1.13M | $534,405 |
| Cash flow statement | ||
| Operating cash flow | $569,214 | -$394,330 |
| Capital expenditure | $69,916 | $52,736 |
| Free cash flow | $499,298 | -$447,066 |
| Investing cash flow | -$2.45M | -$40,796 |
| Financing cash flow | $2.00M | $537,315 |
| Depreciation & amortization | $66,091 | $58,235 |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.